- Home
- DENN vs ATYR Comparison
DENN vs ATYR Comparison
Compare DENN & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DENN
- ATYR
- Stock Information
- Founded
- DENN 1953
- ATYR 2005
- Country
- DENN United States
- ATYR United States
- Employees
- DENN 3500
- ATYR N/A
- Industry
- DENN Restaurants
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DENN Consumer Discretionary
- ATYR Health Care
- Exchange
- DENN Nasdaq
- ATYR Nasdaq
- Market Cap
- DENN 203.4M
- ATYR 330.7M
- IPO Year
- DENN 1989
- ATYR 2015
- Fundamental
- Price
- DENN $3.91
- ATYR $3.68
- Analyst Decision
- DENN Strong Buy
- ATYR Strong Buy
- Analyst Count
- DENN 6
- ATYR 6
- Target Price
- DENN $7.75
- ATYR $18.60
- AVG Volume (30 Days)
- DENN 1.5M
- ATYR 1.9M
- Earning Date
- DENN 04-29-2025
- ATYR 03-13-2025
- Dividend Yield
- DENN N/A
- ATYR N/A
- EPS Growth
- DENN 17.14
- ATYR N/A
- EPS
- DENN 0.41
- ATYR N/A
- Revenue
- DENN $452,334,000.00
- ATYR $235,000.00
- Revenue This Year
- DENN $5.81
- ATYR $1,387.23
- Revenue Next Year
- DENN $2.50
- ATYR $873.22
- P/E Ratio
- DENN $9.59
- ATYR N/A
- Revenue Growth
- DENN N/A
- ATYR N/A
- 52 Week Low
- DENN $3.80
- ATYR $1.42
- 52 Week High
- DENN $9.25
- ATYR $4.66
- Technical
- Relative Strength Index (RSI)
- DENN 28.29
- ATYR 50.20
- Support Level
- DENN $3.80
- ATYR $2.98
- Resistance Level
- DENN $4.11
- ATYR $4.32
- Average True Range (ATR)
- DENN 0.20
- ATYR 0.36
- MACD
- DENN 0.02
- ATYR 0.03
- Stochastic Oscillator
- DENN 14.47
- ATYR 60.37
About DENN Denny's Corporation
Denny's Corp is one of America's franchised full-service restaurant chains based on the number of restaurants. The company owns and operates the Denny's brand and the Keke's Breakfast Cafe brand. It provides Pancakes, Appetizers & Soups, Sandwiches & Salads, Breakfast Melts, Omelets, and others. The company generates its revenue from two sources: the sale of food and beverages and the collection of royalties, advertising revenue, initial and other fees, including occupancy revenue, from restaurants operated by their franchisees.
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.